Journal
EMERGING INFECTIOUS DISEASES
Volume 25, Issue 4, Pages 739-747Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2504.181482
Keywords
-
Categories
Funding
- Calgary Laboratory Services [10015169]
- National Institutes of Health [R01AI090155, R21AI117338]
- NHLS Research Trust
- RESCOM, University of Pretoria
- National Research Foundation
Ask authors/readers for more resources
Klebsiella pneumoniae sequence type (ST) 307 is an emerging global antimicrobial drug-resistant clone. We used whole-genome sequencing and PCR to characterize K. pneumoniae ST307 with oxacillinase (OXA) 181 carbapenemase across several private hospitals in South Africa during 2014-2016. The South Africa ST307 belonged to a different Glade (Glade VI) with unique genomic characteristics when compared with global ST307 (clades I-V). Bayesian evolution analysis showed that Glade VI emerged around March 2013 in Gauteng Province, South Africa, and then evolved during 2014 into 2 distinct lineages. K. pneumoniae ST307 clade VI with OXA-181 disseminated over a 15-month period within 42 hospitals in 23 cities across 6 northeastern provinces, affecting 350 patients. The rapid expansion of ST307 was most likely due to intrahospital, interhospital, intercity, and interprovince movements of patients. This study highlights the importance of molecular surveillance for tracking emerging antimicrobial clones.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available